68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy
Désirèe Deandreis, Paolo Gontero(Fondazione Ricerca Molinette), R. Parise(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Umberto Ricardi(University of Turin), Roberta Carlevato(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Beatrice Lillaz(University of Turin), Marco Oderda(University of Turin), Daniele Giovanni Nicolotti(University of Turin), Sara Bartoncini(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Francesco Ceci(University of Turin), Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Marilena Bellò, Andrea Zitella(University of Turin), Alessia Guarneri(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Emanuela Pilati(University of Turin)
Cited by 39
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
|New England Journal of Medicine|2013|825
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646